Publications

Publications

Sep 28, 2020
Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients
Bell SG, Dalton L, McNeish BL, Fang F, Henry NL, Kidwell KM, McLean K.. Gynecol Oncol. 2020 Aug 23:S0090-8258(20)33816-6. doi: 10.1016/j.ygyno.2020.08.015. Online ahead of print.
Sep 21, 2020
The m(6)A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor
Xiao Y, Thakkar KN, Zhao H, Broughton J, Li Y, Seoane JA, Diep AN, Metzner TJ, von Eyben R, Dill DL, Brooks JD, Curtis C, Leppert JT, Ye J, Peehl DM, Giaccia AJ, Sinha S, Rankin EB.. Proc Natl Acad Sci U S A. 2020 Aug 19:202000516. doi: 10.1073/pnas.2000516117. Online ahead of print.
Jul 31, 2020
Carcinoma-Associated Mesenchymal Stem Cells Promote Chemoresistance in Ovarian Cancer Stem Cells via PDGF Signaling
Raghavan S, Snyder CS, Wang A, McLean K, Zamarin D, Buckanovich RJ, Mehta G.. Cancers (Basel). 2020 Jul 27;12(8):E2063. doi: 10.3390/cancers12082063.
Jun 27, 2020
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study
Zamarin D, Hamid O, Nayak-Kapoor A, Sahebjam S, Sznol M, Collaku A, Fox FE, Marshall MA, Hong DS.. Clin Cancer Res. 2020 Jun 25. doi: 10.1158/1078-0432.CCR-20-0328. Online ahead of print.
Jun 18, 2020
Race and Ethnicity Influence Survival Outcomes in Women of Caribbean Nativity With Epithelial Ovarian Cancer
Schlumbrecht M, Cerbon D, Castillo M, Jordan S, Butler R, Pinto A, George S.. Front Oncol. 2020 May 29;10:880. doi: 10.3389/fonc.2020.00880. eCollection 2020.
Jun 14, 2020
Compressive Stimulation Enhances Ovarian Cancer Proliferation, Invasion, Chemoresistance, and Mechanotransduction via CDC42 in a 3D Bioreactor
Novak CM, Horst EN, Lin E, Mehta G.. Cancers (Basel). 2020 Jun 10;12(6):1521. doi: 10.3390/cancers12061521.
Jun 9, 2020
Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy
Boland JL, Zhou Q, Iasonos AE, O'Cearbhaill RE, Konner J, Callahan M, Friedman C, Aghajanian C, Sabbatini P, Zamarin D, Cadoo KA.. Gynecol Oncol. 2020 Aug;158(2):303-308. doi: 10.1016/j.ygyno.2020.04.710. Epub 2020 Jun 2.
Jun 7, 2020
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial
Zamarin D, Walderich S, Holland A, Zhou Q, Iasonos AE, Torrisi JM, Merghoub T, Chesebrough LF, Mcdonnell AS, Gallagher JM, Li Y, Hollmann TJ, Grisham RN, Erskine CL, Block MS, Knutson KL, O'Cearbhaill RE, Aghajanian C, Konner JA.. J Immunother Cancer. 2020 Jun;8(1):e000829. doi: 10.1136/jitc-2020-000829.
Jun 6, 2020
The associations between physical activity, neuropathy symptoms and health-related quality of life among gynecologic cancer survivors
Thomaier L, Jewett P, Brown K, Gotlieb R, Teoh D, Blaes AH, Argenta P, Vogel RI.. Gynecol Oncol. 2020 Aug;158(2):361-365. doi: 10.1016/j.ygyno.2020.05.026. Epub 2020 Jun 1.
Jun 2, 2020
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Shivange G, Mondal T, Lyerly E, Gatesman J, Tushir-Singh J.. J Vis Exp. 2020 May 16;(159). doi: 10.3791/60727.
May 31, 2020
Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cells
Kang M, Chong KY, Hartwich TMP, Bi F, Witham AK, Patrick D, Morrisson MJ, Cady SL, Cerchia AP, Kelk D, Liu Y, Nucci J, Madarikan O, Ueno D, Shuch BM, Yang-Hartwich Y.. Oncogenesis. 2020 May 29;9(5):55. doi: 10.1038/s41389-020-0243-y.
May 4, 2020
BRCA1 Mutational Complementation Induces Synthetic Viability
Nacson J, Di Marcantonio D, Wang Y, Bernhardy AJ, Clausen E, Hua X, Cai KQ, Martinez E, Feng W, Call?©n E, Wu W, Gupta GP, Testa JR, Nussenzweig A, Sykes SM, Johnson N.. Mol Cell. 2020 Jun 4;78(5):951-959.e6. doi: 10.1016/j.molcel.2020.04.006. Epub 2020 Apr 30.
May 1, 2020
Integrative Transcriptome Analyses of the Human Fallopian Tube: Fimbria and Ampulla-Site of Origin of Serous Carcinoma of the Ovary
Sowamber R, Nelson O, Dodds L, DeCastro V, Paudel I, Milea A, Considine M, Cope L, Pinto A, Schlumbrecht M, Slomovitz B, Shaw PA, George SHL.. Cancers (Basel). 2020 Apr 27;12(5):1090. doi: 10.3390/cancers12051090.
May 1, 2020
Signals from the Metastatic Niche Regulate Early and Advanced Ovarian Cancer Metastasis through miR-4454 Downregulation
Dasari S, Pandhiri T, Grassi T, Visscher DW, Multinu F, Agarwal K, Mariani A, Shridhar V, Mitra AK.. Mol Cancer Res. 2020 Aug;18(8):1202-1217. doi: 10.1158/1541-7786.MCR-19-1162. Epub 2020 Apr 29.
Apr 22, 2020
Inhibition of the Wnt/B-catenin pathway enhances antitumor immunity in ovarian cancer
Doo DW, Meza-Perez S, Londo?±o AI, Goldsberry WN, Katre AA, Boone JD, Moore DJ, Hudson CT, Betella I, McCaw TR, Gangrade A, Bao R, Luke JJ, Yang ES, Birrer MJ, Starenki D, Cooper SJ, Buchsbaum DJ, Norian LA, Randall TD, Arend RC.. Ther Adv Med Oncol. 2020 Apr 14;12:1758835920913798. doi: 10.1177/1758835920913798. eCollection 2020.
Apr 17, 2020
Regenerative Metaplastic Clones in COPD Lung Drive Inflammation and Fibrosis
Rao W, Wang S, Duleba M, Niroula S, Goller K, Xie J, Mahalingam R, Neupane R, Liew AA, Vincent M, Okuda K, O'Neal WK, Boucher RC, Dickey BF, Wechsler ME, Ibrahim O, Engelhardt JF, Mertens TCJ, Wang W, Jyothula SSK, Crum CP, Karmouty-Quintana H, Parekh KR, Metersky ML, McKeon FD, Xian W.. Cell. 2020 May 14;181(4):848-864.e18. doi: 10.1016/j.cell.2020.03.047. Epub 2020 Apr 15.
Apr 11, 2020
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
Zamarin D, Burger RA, Sill MW, Powell DJ Jr, Lankes HA, Feldman MD, Zivanovic O, Gunderson C, Ko E, Mathews C, Sharma S, Hagemann AR, Khleif S, Aghajanian C.. J Clin Oncol. 2020 Jun 1;38(16):1814-1823. doi: 10.1200/JCO.19.02059. Epub 2020 Apr 10.
Apr 9, 2020
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect
Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, Rachmilewitz Minei T, Harats D, Wall JA, Foxall ME, Penson RT.. Gynecol Oncol. 2020 Jun;157(3):578-584. doi: 10.1016/j.ygyno.2020.02.034. Epub 2020 Apr 5.
Apr 3, 2020
Cloning of ground-state intestinal stem cells from endoscopic biopsy samples
Duleba M, Yamamoto Y, Neupane R, Rao W, Xie J, Qi Y, Liew AA, Niroula S, Zhang Y, Mahalingam R, Wang S, Goller K, Ajani JA, Vincent M, Ho KY, Hou JK, Hyams JS, Sylvester FA, Crum CP, McKeon F, Xian W.. Nat Protoc. 2020 May;15(5):1612-1627. doi: 10.1038/s41596-020-0298-4. Epub 2020 Apr 1.
Mar 28, 2020
Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment
Goldsberry WN, Meza-Perez S, Londo?±o AI, Katre AA, Mott BT, Roane BM, Goel N, Wall JA, Cooper SJ, Norian LA, Randall TD, Birrer MJ, Arend RC.. Cancers (Basel). 2020 Mar 24;12(3):766. doi: 10.3390/cancers12030766.
Mar 28, 2020
RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1-Null Cancers
Krais JJ, Wang Y, Bernhardy AJ, Clausen E, Miller JA, Cai KQ, Scott CL, Johnson N.. Cancer Res. 2020 Jul 1;80(13):2848-2860. doi: 10.1158/0008-5472.CAN-19-3033. Epub 2020 Mar 25.
Mar 21, 2020
Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer
Betella I, Turbitt WJ, Szul T, Wu B, Martinez A, Katre A, Wall JA, Norian L, Birrer MJ, Arend R.. Gynecol Oncol. 2020 Jun;157(3):765-774. doi: 10.1016/j.ygyno.2020.03.010. Epub 2020 Mar 16.
Mar 18, 2020
Ectopic RNF168 expression promotes break-induced replication-like DNA synthesis at stalled replication forks
Krais JJ, Johnson N.. Nucleic Acids Res. 2020 May 7;48(8):4298-4308. doi: 10.1093/nar/gkaa154.
Feb 25, 2020
Cancer-Related Distress: Revisiting the Utility of the National Comprehensive Cancer Network Distress Thermometer Problem List in Women With Gynecologic Cancers
Jewett PI, Teoh D, Petzel S, Lee H, Messelt A, Kendall J, Hatsukami D, Everson-Rose SA, Blaes AH, Vogel RI.. JCO Oncol Pract. 2020 Aug;16(8):e649-e659. doi: 10.1200/JOP.19.00471. Epub 2020 Feb 24.
Feb 13, 2020
Large, Non-Cavity Distorting Intramural Leiomyomas Decrease Leukemia Inhibitory Factor in the Secretory Phase Endometrium
Pier B, Crellin C, Katre A, Conner MG, Novak L, Young SL, Arend R.. Reprod Sci. 2020 Feb;27(2):569-574. doi: 10.1007/s43032-019-00056-x. Epub 2020 Jan 1.
Feb 9, 2020
Implementation of a standardized voiding management protocol to reduce unnecessary re-catheterization - A quality improvement project
Brackmann M, Carballo E, Uppal S, Torski J, Reynolds RK, McLean K.. Gynecol Oncol. 2020 May;157(2):487-493. doi: 10.1016/j.ygyno.2020.01.036. Epub 2020 Feb 5.
Feb 1, 2020
Preparation of single cells from tumors for single-cell RNA sequencing
Vijayakumar G, Zamarin D.. Methods Mol Biol. 2020;2058:133-154. doi: 10.1007/978-1-4939-9794-7_9.
Dec 25, 2019
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade
Arend RC, Davis AM, Chimiczewski P, O'Malley DM, Provencher D, Vergote I, Ghamande S, Birrer MJ.. Gynecol Oncol. 2020 Feb;156(2):301-307. doi: 10.1016/j.ygyno.2019.12.002. Epub 2019 Dec 20.
Dec 18, 2019
Sun exposure and protection behaviors in urban and rural long-term melanoma survivors
Jewett PI, Lazovich D, Wehelie H, Boull C, Vogel RI.. Arch Dermatol Res. 2020 Aug;312(6):413-420. doi: 10.1007/s00403-019-02023-7. Epub 2019 Dec 16.
Dec 13, 2019
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
Wang Y, Bernhardy AJ, Nacson J, Krais JJ, Tan YF, Nicolas E, Radke MR, Handorf E, Llop-Guevara A, Balma?±a J, Swisher EM, Serra V, Peri S, Johnson N.. Nat Commun. 2019 Dec 11;10(1):5661. doi: 10.1038/s41467-019-13530-6.
Dec 5, 2019
Endometrial cancer among a cohort of urban Haitian immigrants
Schlumbrecht M, Bussies P, Huang M, Kobetz E, George S.. World J Clin Oncol. 2019 Oct 24;10(10):340-349. doi: 10.5306/wjco.v10.i10.340.
Nov 16, 2019
Neoadjuvant Treatment With Mullerian-Inhibiting Substance Synchronizes Follicles and Enhances Superovulation Yield
Kano M, Hsu JY, Saatcioglu HD, Nagykery N, Zhang L, Morris Sabatini ME, Donahoe PK, Pepin D.. J Endocr Soc. 2019 Jul 22;3(11):2123-2134. doi: 10.1210/js.2019-00190. eCollection 2019 Nov 1.
Oct 12, 2019
Transcriptome Profiling Reveals Matrisome Alteration as a Key Feature of Ovarian Cancer Progression
Mitra S, Tiwari K, Podicheti R, Pandhiri T, Rusch DB, Bonetto A, Zhang C, Mitra AK. Cancers (Basel). 2019 Oct 9;11(10):1513. doi: 10.3390/cancers11101513.
Oct 6, 2019
S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma
Xiao Y, Zhao H, Tian L, Nolley R, Diep AN, Ernst A, Fuh KC, Miao YR, von Eyben R, Leppert JT, Brooks JD, Peehl DM, Giaccia AJ, Rankin EB. Cancer Res. 2019 Nov 15;79(22):5758-5768. doi: 10.1158/0008-5472.CAN-19-1366. Epub 2019 Oct 4.
Sep 6, 2019
Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation
Vijayakumar G, Zamarin D.. Methods Mol Biol. 2020;2058:133-154. doi: 10.1007/978-1-4939-9794-7_9.
Aug 21, 2019
Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance.
Ward Rashidi MR, Mehta P, Bregenzer M, Raghavan S, Fleck EM, Horst EN, Harissa Z, Ravikumar V, Brady S, Bild A, Rao A, Buckanovich RJ, Mehta G. Neoplasia. 2019 Aug;21(8):822-836. doi: 10.1016/j.neo.2019.06.005. PMID 31299607
Aug 14, 2019
Differences in breast cancer outcomes amongst Black US-born and Caribbean-born immigrants.
Barreto-Coelho P, Cerbon D, Schlumbrecht M, Parra CM, Hurley J, George SHL. Breast Cancer Res Treat. 2019 Aug 14. doi: 10.1007/s10549-019-05403-9. PMID 31414243
Aug 14, 2019
Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.
Liu YL, Zhou Q, Iasonos A, Emengo VN, Friedman C, Konner JA, O'Cearbhaill RE, Aghajanian C, Zamarin D. Gynecol Oncol. 2019 Aug 14. pii: S0090-8258(19)31457-X. doi: 10.1016/j.ygyno.2019.08.006. PMID 31421916
Aug 9, 2019
Inhibition of Heat Shock Protein 90 suppresses TWIST1 Transcription.
Chong KY, Kang M, Garofalo F, Ueno D, Liang H, Cady S, Madarikan O, Pitruzzello N, Tsai CH, Hartwich TMP, Shuch BM, Yang-Hartwich Y. Mol Pharmacol. 2019 Aug;96(2):168-179. doi: 10.1124/mol.119.116137. PMID 31175180
Aug 6, 2019
Unlimited expansion of intestinal stem cells from a wide range of ages.
Duleba M, Mahalingam R, Liew AA, Qi Y, Neupane R, Vincent M, Agarwal S, Sylvester FA, Hyams JS, Ho KY, Hou JK, McKeon F, Xian W. Integr Mol Med. 2019 Aug;6(4). doi: 10.15761/IMM.1000375. PMID 31463081 (Abstract only)
Jul 19, 2019
IRE1?-XBP1 signaling in leukocytes controls prostaglandin biosynthesis and pain.
Chopra S, Giovanelli P, Alvarado-Vazquez PA, Alonso S, Song M, Sandoval TA, Chae CS, Tan C, Fonseca MM, Gutierrez S, Jimenez L, Subbaramai+E2ah K, Iwawaki T, Kingsley PJ, Marnett LJ, Kossenkov AV, Crespo MS, Dannenberg AJ, Glimcher LH, Romero-Sandoval EA, Cubillos-Ruiz JR. Science. 2019 Jul 19;365(6450). pii: eaau6499. doi: 10.1126/science.aau6499. PMID 31320508
Jul 19, 2019
Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments.
Raghavan S, Mehta P, Xie Y, Lei YL, Mehta G. J Immunother Cancer. 2019 Jul 19;7(1):190. doi: 10.1186/s40425-019-0666-1. PMID 31324218
Jul 17, 2019
Neutrophilia and mortality in women with uterine carcinosarcoma.
Arend R, Van Arsdale A, Gojayev A, Roane BM, Doo D, Leath C, Goldberg GL, Huang G. Int J Gynecol Cancer. 2019 Jul 17. pii: ijgc-2019-000440. doi: 10.1136/ijgc-2019-000440. PMID 31320488. Int J Gynecol Cancer. 2019 Jul 17. pii: ijgc-2019-000440. doi: 10.1136/ijgc-2019-000440. PMID 31320488
Jul 17, 2019
Fluid shear stress stimulates breast cancer cells to display invasive and chemoresistant phenotypes while upregulating PLAU in a 3D bioreactor.
Novak CM, Horst EN, Taylor CC, Liu CZ, Mehta G. Biotechnol Bioeng. 2019 Jul 17. doi: 10.1002/bit.27119. PMID 31317530
Jul 5, 2019
Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells.
Bregenzer ME, Davis C, Horst EN, Mehta P, Novak CM, Raghavan S, Snyder CS, Mehta G. J Vis Exp. 2019 Jul 5;(149). doi: 10.3791/59696. PMID 31329171
Jun 24, 2019
Single-cell sequencing of neonatal uterus reveals an Misr2+ endometrial progenitor indispensable for fertility.
Saatcioglu HD, Kano M, Horn H, Zhang L, Samore W, Nagykery N, Meinsohn MC, Hyun M, Suliman R, Poulo J, Hsu J, Sacha C, Wang D, Gao G, Lage K, Oliva E, Morris Sabatini ME, Donahoe PK, Pépin D.
Jun 11, 2019
Morphometric and computational assessments to evaluate neuron survival and maturation within compartmentalized microfluidic devices: The influence of design variation on diffusion-driven nutrient transport.
Dixon AR, Horst EN, Garcia JJ, Ndjouyep-Yamaga PR, Mehta G. Neurosci Lett. 2019 Jun 11;703:58-67. doi: 10.1016/j.neulet.2019.03.025. PMID 30885631
Jun 4, 2019
CCAAT/enhancer binding protein delta (C/EBP?) demonstrates a dichotomous role in tumour initiation and promotion of epithelial carcinoma.
Sowamber R, Chehade R, Bitar M, Dodds LV, Milea A, Slomovitz B, Shaw PA, George SHL. EBioMedicine. 2019 Jun;44:261-274. doi: 10.1016/j.ebiom.2019.05.002. PMID 31078521
May 15, 2019
Identifying disparities in germline and somatic testing for ovarian cancer.
Huang M, Kamath P, Schlumbrecht M, Miao F, Driscoll D, Oldak S, Slomovitz B, Koru-Sengul T, George S. Gynecol Oncol. 2019 May;153(2):297-303. doi: 10.1016/j.ygyno.2019.03.007. PMID 30890269
May 10, 2019
Integrated cancer tissue engineering models for precision medicine.
Bregenzer ME, Horst EN, Mehta P, Novak CM, Raghavan S, Snyder CS, Mehta G. PLoS One. 2019 May 10;14(5):e0216564. doi: 10.1371/journal.pone.0216564. PMID 31232694
May 3, 2019
Endometrial cancer outcomes among non-Hispanic US born and Caribbean born black women.
Schlumbrecht M, Huang M, Hurley J, George S. Int J Gynecol Cancer. 2019 May 3. pii: ijgc-2019-000347. doi: 10.1136/ijgc-2019-000347. PMID 31055453
May 1, 2019
Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis.
Natarajan S, Foreman KM, Soriano MI, Rossen NS, Shehade H, Fregoso DR, Eggold JT, Krishnan V, Dorigo O, Krieg AJ, Heilshorn SC, Sinha S, Fuh KC, Rankin EB. Cancer Res. 2019 May 1;79(9):2271-2284. doi: 10.1158/0008-5472.CAN-18-2616. PMID 30862717
Apr 15, 2019
A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.
Vogel RI, Niendorf K, Petzel S, Lee H, Teoh D, Blaes AH, Argenta P, Rivard C, Winterhoff B, Lee HY, Geller MA. Gynecol Oncol. 2019 Apr;153(1):100-107. doi: 10.1016/j.ygyno.2019.01.019. PMID 30718125
Apr 12, 2019
Patient satisfaction with patient-provider interactions at time of diagnosis among early stage melanoma survivors - a cross-sectional survey.
Zaffran K, Lazovich D, Boull C, Vogel RI. J Am Acad Dermatol. 2019 Apr 12. pii: S0190-9622(19)30600-0. doi: 10.1016/j.jaad.2019.04.014. PMID 30986476
Mar 20, 2019
Targeting HER2 beyond breast cancer.
Bhatnagar S, Tushir-Singh J. Mol Cell Oncol. 2019 Mar 20;6(3):1571984. doi: 10.1080/23723556.2019.1571984. PMID 31131305
Feb 15, 2019
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, Tew W, Makker V, Grisham RN, Hensley ML, Zecca N, Iasonos AE, Snyder A, Hyman DM, Sabbatini P, Aghajanian C, Cadoo KA, Zamarin D. Gynecol Oncol. 2019 Feb;152(2):251-258. doi: 10.1016/j.ygyno.2018.11.025. PMID 30470581
Feb 3, 2019
Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
McLean K, Tan L, Bolland DE, Coffman LG, Peterson LF, Talpaz M, Neamati N, Buckanovich RJ. Oncogene. 2019 Feb;38(9):1576-1584. doi: 10.1038/s41388-018-0523-6. PMID 30305729
Jan 17, 2019
p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT.
Yang-Hartwich Y, Tedja R, Roberts CM, Goodner-Bingham J, Cardenas C, Gurea M, Sumi NJ, Alvero AB, Glackin CA, Mor G. Mol Cancer Res. 2019 Jan;17(1):153-164. doi: 10.1158/1541-7786.MCR-18-0238. PMID 30131448
Jan 15, 2019
An Efficient Method for Cloning Gastrointestinal Stem Cells from Patients via Endoscopic Biopsies.
Duleba M, Qi Y, Mahalingam R, Flynn K, Rinaldi F, Liew AA, Neupane R, Vincent M, Crum CP, Ho KY, Hou JK, Hyams JS, Sylvester FA, McKeon F, Xian W. Gastroenterology. 2019 Jan;156(1):20-23. doi: 10.1053/j.gastro.2018.08.062. PMID 30296437
Jan 11, 2019
Evaluation of graphic messages to promote human papillomavirus vaccination among young adults: A statewide cross-sectional survey.
Teoh D, Shaikh R, Schnaith A, Lou E, McRee AL, Nagler RH, Vogel RI. Prev Med Rep. 2019 Jan 11;13:256-261. doi: 10.1016/j.pmedr.2019.01.002. PMID 30723659
Dec 20, 2018
The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival.
Hacker KE, Bolland DE, Tan L, Saha AK, Niknafs YS, Markovitz DM, McLean K. Neoplasia. 2018 Dec;20(12):1209-1218. doi: 10.1016/j.neo.2018.10.005. PMID 30412857
Dec 15, 2018
The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Smith HJ, McCaw TR, Londono AI, Katre AA, Meza-Perez S, Yang ES, Forero A, Buchsbaum DJ, Randall TD, Straughn JM Jr, Norian LA, Arend RC. Cancer. 2018 Dec 15;124(24):4657-4666. doi: 10.1002/cncr.31761 PMID 30423192
Oct 6, 2018
A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families
Donenberg T, George S, Ali J, Bravo G, Hernandez K, Sookar N, Ashing KT, Narod SA, Akbari MR, Hurley J. Breast Cancer Res Treat. 2019 Apr;174(2):469-477. doi: 10.1007/s10549-018-5045-y. Epub 2018 Dec 4.
Oct 5, 2018
IRE1?-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity
Song M, Sandoval TA, Chae CS, Chopra S, Tan C, Rutkowski MR, Raundhal M, Chaurio RA, Payne KK, Konrad C, Bettigole SE, Shin HR, Crowley MJP, Cerliani JP, Kossenkov AV, Motorykin I, Zhang S, Manfredi G, Zamarin D, Holcomb K, Rodriguez PC, Rabinovich GA, Conejo-Garcia JR, Glimcher LH, Cubillos-Ruiz JR. Nature. 2018 Oct;562(7727):423-428. doi: 10.1038/s41586-018-0597-x. PMID 30305738
Sep 25, 2018
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
Nacson J, Krais JJ, Bernhardy AJ, Clausen E, Feng W, Wang Y, Nicolas E, Cai KQ, Tricarico R, Hua X, DiMarcantonio D, Martinez E, Zong D, Handorf EA, Bellacosa A, Testa JR, Nussenzweig A, Gupta GP, Sykes SM, Johnson N. Cell Rep. 2018 Sep 25;24(13):3513-3527.e7. doi: 10.1016/j.celrep.2018.08.086. PMID 30257212
Aug 28, 2018
A Proximal Culture Method to Study Paracrine Signaling Between Cells.
Dasari S, Pandhiri T, Haley J, Lenz D, Mitra AK. J Vis Exp. 2018 Aug 28;(138). doi: 10.3791/58144. PMID 30222146
Aug 13, 2018
A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer.
Shivange G, Urbanek K, Przanowski P, Perry JSA, Jones J, Haggart R, Kostka C, Patki T, Stelow E, Petrova Y, Llaneza D, Mayo M, Ravichandran KS, Landen CN, Bhatnagar S, Tushir-Singh J. Cancer Cell. 2018 Aug 13;34(2):331-345.e11. doi: 10.1016/j.ccell.2018.07.005. PMID 30107179
Jul 19, 2018
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
Oseledchyk A, Ricca JM, Gigoux M, Ko B, Redelman-Sidi G, Walther T, Liu C, Iyer G, Merghoub T, Wolchok JD, Zamarin D. Oncotarget. 2018 Jun 19;9(47):28702-28716. doi: 10.18632/oncotarget.25614. PMID 29983890
Jul 4, 2018
A qualitative study of barriers to genetic counseling and potential for mobile technology education among women with ovarian cancer.
Vogel RI, Niendorf K, Lee H, Petzel S, Lee HY, Geller MA. Hered Cancer Clin Pract. 2018 Jul 4;16:13. doi: 10.1186/s13053-018-0095-z. PMID 29997716
Jul 1, 2018
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
Jelinic P, Ricca J, Van Oudenhove E, Olvera N, Merghoub T, Levine DA, Zamarin D. J Natl Cancer Inst. 2018 Jul 1;110(7):787-790. doi: 10.1093/jnci/djx277. PMID 29365144
Jun 29, 2018
Effect of intra-operative glove changing during cesarean section on post-operative complications: a randomized controlled trial.
Scrafford JD, Reddy B, Rivard C, Vogel RI. Arch Gynecol Obstet. 2018 Jun;297(6):1449-1454. doi: 10.1007/s00404-018-4748-y. PMID 29556706
Jun 1, 2018
Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche.
Condello S, Sima L, Ivan C, Cardenas H, Schiltz G, Mishra RK, Matei D. Cancer Res. 2018 Jun 1;78(11):2990-3001. doi: 10.1158/0008-5472.CAN-17-2319. PMID 29510995
May 16, 2018
Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.
Arend RC, Londoño AI, Montgomery AM, Smith HJ, Dobbin ZC, Katre AA, Martinez A, Yang ES, Alvarez RD, Huh WK, Bevis KS, Straughn JM Jr, Estes JM, Novak L, Crossman DK, Cooper SJ, Landen CN, Leath CA 3rd. Mol Cancer Res. 2018 May;16(5):813-824. doi: 10.1158/1541-7786.MCR-17-0594 PMID 29523763
Apr 4, 2018
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, Wolchok JD, Zamarin D. Mol Ther. 2018 Apr 4;26(4):1008-1019. doi: 10.1016/j.ymthe.2018.01.019. PMID 29478729
Apr 2, 2018
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, Wong J, Gigoux M, Merghoub T, Wolchok JD. J Clin Invest. 2018 Apr 2;128(4):1413-1428. doi: 10.1172/JCI98047. PMID 29504948
Mar 7, 2018
Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma.
Van Arsdale AR, Arend RC, Cossio MJ, Erickson BK, Wang Y, Doo DW, Leath CA, Goldberg GL, Huang GS. Cancer Med. 2018 Mar;7(3):616-625. doi: 10.1002/cam4.1335 PMID 29455465
Feb 1, 2018
ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.
Tomar S, Plotnik JP, Haley J, Scantland J, Dasari S, Sheikh Z, Emerson R, Lenz D, Hollenhorst PC, Mitra AK. Cancer Lett. 2018 Feb 1;414:190-204. doi: 10.1016/j.canlet.2017.11.012. PMID 29174800
Nov 15, 2017
Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
Raghavan S, Mehta P, Ward MR, Bregenzer ME, Fleck EMA, Tan L, McLean K, Buckanovich RJ, Mehta G. Clin Cancer Res. 2017 Nov 15;23(22):6934-6945. doi: 10.1158/1078-0432.CCR-17-0133. PMID 28814433
Jul 26, 2017
Comparison of quality of life among long-term melanoma survivors and non-melanoma controls: a cross-sectional study.
Vogel RI, Strayer LG, Engelman L, Nelson HH, Blaes AH, Anderson KE, Lazovich D. Qual Life Res. 2017 Jul;26(7):1761-1766. doi: 10.1007/s11136-017-1532-6. PMID 28243994
Jul 4, 2017
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Turner TB, Meza-Perez S, Londoño A, Katre A, Peabody JE, Smith HJ, Forero A, Norian LA, Straughn JM Jr, Buchsbaum DJ, Randall TD, Arend RC. Oncotarget. 2017 Jul 4;8(27):44159-44170. doi: 10.18632/oncotarget.17395. PMID 28498806
Jun 27, 2017
Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer.
Morse CB, Elvin JA, Gay LM, Liao JB. Gynecol Oncol Rep. 2017 Jun 27;21:78-80. doi: 10.1016/j.gore.2017.06.013. Gynecol Oncol Rep. 2017 Jun 27;21:78-80. doi: 10.1016/j.gore.2017.06.013. PMID 28736741
Apr 26, 2017
Sun Exposure and Protection Behaviors among Long-term Melanoma Survivors and Population Controls.
Vogel RI, Strayer LG, Engelman L, Nelson HH, Blaes AH, Anderson KE, Lazovich D. Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):607-613. doi: 10.1158/1055-9965.EPI-16-0854. PMID 28254810
Mar 2, 2017
Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells.
Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley TD, Matei D, Cheng JX. Cell Stem Cell. 2017 Mar 2;20(3):303-314.e5. doi: 10.1016/j.stem.2016.11.004. PMID 28041894
Mar 1, 2017
Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer.
Liao JB, Swensen RE, Ovenell KJ, Hitchcock-Bernhardt KM, Reichow JL, Apodaca MC, D'Amico L, Childs JS, Higgins DM, Buening BJ, Goff BA, Disis ML. Gynecol Oncol. 2017 Mar;144(3):480-485. doi: 10.1016/j.ygyno.2017.01.008. PMID 28089377
Feb 28, 2017
AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy.
Kano M, Sosulski AE, Zhang L, Saatcioglu HD, Wang D, Nagykery N, Sabatini ME, Gao G, Donahoe PK, Pépin D. Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):E1688-E1697. doi: 10.1073/pnas.1620729114. PMID 28137855
Feb 13, 2017
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.
Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Nat Commun. 2017 Feb 13;8:14340. doi: 10.1038/ncomms14340. PMID 28194010
Jan 15, 2017
In Vitro Assay to Study Histone Ubiquitination During Transcriptional Regulation.
Tushir-Singh J, Bhatnagar S. Methods Mol Biol. 2017;1507:235-244. PMID 27832544
Dec 27, 2016
Niclosamide and its analogs are potent inhibitors of Wnt/?-catenin, mTOR and STAT3 signaling in ovarian cancer.
Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Oncotarget. 2016 Dec 27;7(52):86803-86815. doi: 10.18632/oncotarget. PMID 27888804
Oct 15, 2016
VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal
Bastola P, Neums L, Schoenen FJ, Chien J. VCP inhibitors induce endoplasmicreticulum stress, cause cell cycle arrest, trigger caspase-mediated celldeath and synergistically kill ovarian cancer cells in combination withSalubrinal. Mol Oncol. 2016 Sep 28. pii: S1574-7891(16)30104-1. doi:10.1016/j.molonc.2016.09.005. PubMed PMID: 27729194.
Sep 13, 2016
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Kossenkov AV, Bradner JE, Conejo-Garcia JR, Zhang R. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Rep. 2016 Sep 13;16(11):2829-37. doi: 10.1016/j.celrep.2016.08.032. PubMed PMID: 27626654.
Aug 2, 2016
Primary Peritoneal Carcinoma in a BRCA1/2-negative, PALB2-positive patient.
Kahn R, Garcia-Soto A, Silva-Smith R, Pinto A, George SH. Gynecol Oncol Rep. 2016 Aug 2;17:93-5. doi: 10.1016/j.gore.2016.08.001. PMID 27547810
Aug 1, 2016
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N. J Clin Invest. 2016 Aug 1;126(8):3145-57. doi: 10.1172/JCI87033. PMID 27454289
Jun 2, 2016
CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.
Sosulski A, Horn H, Zhang L, Coletti C, Vathipadiekal V, Castro CM, Birrer MJ, Nagano O, Saya H, Lage K, Donahoe PK, Pépin D. PLoS One. 2016 Jun 2;11(6):e0156595. doi: 10.1371/journal.pone.0156595. PMID 27253518
May 31, 2016
Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.
Haley J, Tomar S, Pulliam N, Xiong S, Perkins SM, Karpf AR, Mitra S, Nephew KP, Mitra AK. Oncotarget. 2016 May 31;7(22):32810-20. doi: 10.18632/oncotarget.9053. PMID 27147568
May 27, 2016
A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients
Poole EM, Kubzansky LD, Sood AK, Okereke OI, Tworoger SS. A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. Cancer Causes Control. 2016 May;27(5):661-8. doi: 10.1007/s10552-016-0739-0. Epub 2016
Mar 29. PubMed PMID: 27023470; PubMed Central PMCID: PMC4840033.
May 24, 2016
USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment.
Vogel RI, Pulver T, Heilmann W, Mooneyham A, Mullany S, Zhao X, Shahi M, Richter J, Klein M, Chen L, Ding R, Konecny G, Kommoss S, Winterhoff B, Ghebre R, Bazzaro M. Oncotarget. 2016 May 24;7(21):30962-76. doi: 10.18632/oncotarget.8821. PMID 27121063
May 14, 2016
Prognostic implications of reproductive and lifestyle factors in ovarian cancer
Poole EM, Konstantinopoulos PA, Terry KL. Prognostic implications of reproductive and lifestyle factors in ovarian cancer. Gynecol Oncol. 2016 May 14. pii: S0090-8258(16)30733-8. doi: 10.1016/j.ygyno.2016.05.014. [Epub ahead of print] Review. PubMed PMID: 27189457.
May 1, 2016
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK; kConFab Investigators, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N. The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res. 2016 May 1;76(9):2778-90. doi: 10.1158/0008-5472.CAN-16-0186. PubMed PMID: 27197267; PubMed Central PMCID: PMC4874568. Abstract
May 1, 2016
The BRCA1-?11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK; kConFab Investigators, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N. Cancer Res. 2016 May 1;76(9):2778-90. doi: 10.1158/0008-5472.CAN-16-0186. PMID 27197267
Apr 27, 2016
Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease
Haley J, Tomar S, Pulliam N, Xiong S, Perkins SM, Karpf AR, Mitra S, Nephew KP, Mitra AK. Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease. Oncotarget. 2016 Apr 27. doi: 10.18632/oncotarget.9053. [Epub ahead of print] PubMed PMID: 27147568.
Mar 29, 2016
Comparative analysis of tumor spheroid generation techniques for differential in vitro drug toxicity
Raghavan S, Mehta P, Horst EN, Ward MR, Rowley KR, Mehta G. Comparative analysis of tumor spheroid generation techniques for differential in vitro drug toxicity. Oncotarget. 2016 Mar 29;7(13):16948-61. doi: 10.18632/oncotarget.7659. PubMed PMID: 26918944.
Mar 29, 2016
Comparative analysis of tumor spheroid generation techniques for differential in vitro drug toxicity.
Raghavan S, Mehta P, Horst EN, Ward MR, Rowley KR, Mehta G. Oncotarget. 2016 Mar 29;7(13):16948-61. doi: 10.18632/oncotarget.7659. PMID 26918944
Mar 23, 2016
In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells.
Yamamoto Y, Ning G, Howitt BE, Mehra K, Wu L, Wang X, Hong Y, Kern F, Wei TS, Zhang T, Nagarajan N, Basuli D, Torti S, Brewer M, Choolani M, McKeon F, Crum CP, Xian W. J Pathol. 2016 Mar;238(4):519-530. doi: 10.1002/path.4649. PMID 26415052
Mar 22, 2016
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22;7(12):13587-98. doi: 10.18632/oncotarget.7277. PubMed PMID: 26871470.
Jan 26, 2016
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D. Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep. 2016 Jan 26;14(3):429-39.
doi: 10.1016/j.celrep.2015.12.046. Epub 2016 Jan 7. PubMed PMID: 26774475; PubMed
Central PMCID: PMC4731274.
Jan 19, 2016
Mutational spectrum of Barrett's stem cells suggests paths to initiation of a precancerous lesion.
Yamamoto Y, Wang X, Bertrand D, Kern F, Zhang T, Duleba M, Srivastava S, Khor CC, Hu Y, Wilson LH, Blaszyk H, Rolshud D, Teh M, Liu J, Howitt BE, Vincent M, Crum CP, Nagarajan N, Ho KY, McKeon F, Xian W. Nat Commun. 2016 Jan 19;7:10380. doi: 10.1038/ncomms10380. PMID 26783136
Aug 13, 2015
In vivo tumor growth of high-grade serous ovarian cancer cell lines.
Mitra AK, Davis DA, Tomar S, Roy L, Gurler H, Xie J, Lantvit DD, Cardenas H, Fang F, Liu Y, Loughran E, Yang J, Sharon Stack M, Emerson RE, Cowden Dahl KD, V Barbolina M, Nephew KP, Matei D, Burdette JE. Gynecol Oncol. 2015 Aug;138(2):372-7. doi: 10.1016/j.ygyno.2015.05.040. PMID 26050922
Aug 11, 2015
AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Pépin D, Sosulski A, Zhang L, Wang D, Vathipadiekal V, Hendren K, Coletti CM, Yu A, Castro CM, Birrer MJ, Gao G, Donahoe PK. Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4418-27. doi: 10.1073/pnas.1510604112. PMID 26216943
Jul 13, 2015
Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.
Raghavan S, Ward MR, Rowley KR, Wold RM, Takayama S, Buckanovich RJ, Mehta G. Gynecol Oncol. 2015 Jul;138(1):181-9. doi: 10.1016/j.ygyno.2015.04.014. PMID: 25913133
Jun 18, 2015
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.
Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, Zhang S, Bettigole SE, Gupta D, Holcomb K, Ellenson LH, Caputo T, Lee AH, Conejo-Garcia JR, Glimcher LH. Cell. 2015 Jun 18;161(7):1527-38. doi: 10.1016/j.cell.2015.05.025. PMID 26073941
Jun 13, 2015
Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates.
Liao JB, Yip YY, Swisher EM, Agnew K, Hellstrom KE, Hellstrom I. Gynecol Oncol. 2015 Jun;137(3):430-5. doi: 10.1016/j.ygyno.2015.03.044. PMID: 25866324
Jun 11, 2015
Cloning and variation of ground state intestinal stem cells.
Wang X, Yamamoto Y, Wilson LH, Zhang T, Howitt BE, Farrow MA, Kern F, Ning G, Hong Y, Khor CC, Chevalier B, Bertrand D, Wu L, Nagarajan N, Sylvester FA, Hyams JS, Devers T, Bronson R, Lacy DB, Ho KY, Crum CP, McKeon F, Xian W. Nature. 2015 Jun 11;522(7555):173-8. doi: 10.1038/nature14484. PMID 26040716
May 19, 2015
Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer.
Liao JB, Ovenell KJ, Curtis EE, Cecil DL, Koehnlein MR, Rastetter LR, Gad EA, Disis ML. J Immunother Cancer. 2015 May 19;3:16. doi: 10.1186/s40425-015-0060-6. PMID: 25992288
Feb 28, 2015
Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells.
Vogel RI, Coughlin K, Scotti A, Iizuka Y, Anchoori R, Roden RB, Marastoni M, Bazzaro M. Oncotarget. 2015 Feb 28;6(6):4159-70. PMID 25784654
Feb 25, 2015
Clinical response to antiestrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status.
Stasenko M, Plegue M, Sciallis AP, McLean K. Int J Gynecol Cancer. 2015 Feb;25(2):222-8. doi: 10.1097/IGC.0000000000000334. PMID: 25500503